Previous 10 | Next 10 |
2023-05-04 17:54:55 ET Merus press release ( NASDAQ: MRUS ): Q1 GAAP EPS of -$0.86 beats by $0.17 . Revenue of $13.5M (+15.8% Y/Y) beats by $2.21M . For further details see: Merus GAAP EPS of -$0.86 beats by $0.17, revenue of $13.5M beats by $2.21M
– Petosemtamab clinical update presented at the American Association of Cancer Research (AACR) Annual Meeting 2023 – Petosemtamab end-of-phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in head and neck squamous cell carcin...
2023-04-17 12:55:02 ET Dutch biotech Merus ( NASDAQ: MRUS ) gained ~13% on Monday after announcing interim data for its bispecific antibody petosemtamab from a Phase 1/2 trial in previously treated head and neck squamous cell carcinoma (HNSCC). Citing a presentation at the o...
- 37% overall response rate (ORR) observed in 43 evaluable patients - 6 months median duration of response as of Feb. 1, 2023 data cutoff date - End-of-phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in HNSCC - Investor call on April 17...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced t...
- Robust 36% overall response rate (ORR) in 42 evaluable patients - 6 months median duration of response with 17 patients still on treatment as of Nov. 28, 2022 data cutoff - End-of-Phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in...
2023-04-04 09:28:45 ET Summary Merus N.V. develops bispecific and trispecific antibodies for cancer. They have deals with an array of big pharma. The lead asset may file a BLA soon. Merus N.V. ( MRUS ) is a Dutch developer of antibody therapeutics targeting c...
2023-03-15 12:01:09 ET Merus N.V. ( NASDAQ: MRUS ) added ~7% on Wednesday to reach the highest level since November after announcing that abstracts on its MCLA-158 and MCLA-129 product candidates were selected for presentations at the upcoming AACR Annual Meeting. The ...
The following slide deck was published by Merus N.V. in conjunction with this event. For further details see: Merus (MRUS) Presents At J.P. Morgan Healthcare Conference
Merus press release ( NASDAQ: MRUS ): Q4 GAAP EPS of -$2.92. Revenue of $41.59M (-0.7% Y/Y) misses by $7.51M . For further details see: Merus GAAP EPS of -$2.92, revenue of $41.59M misses by $7.51M
News, Short Squeeze, Breakout and More Instantly...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...
2024-07-13 04:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...